To demonstrate non-inferiority of gadobutrol versus gadobenate dimeglumine by intra-individually comparing 0.1 mmol/kg body weight doses for contrast-enhanced breast magnetic resonance imaging ( MRI ) and prospectively evaluating lesion detection and characterisation in a multicentre trial .
